Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
HUMA

HUMA - Humacyte, Inc. Stock Price, Fair Value and News

$1.35-0.14 (-9.40%)
Delayed

6/100

HUMA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

HUMA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HUMA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HUMA Price Action

Last 7 days

3.9%

Last 30 days

37.8%

Last 90 days

21.6%

Trailing 12 Months

-48.5%

HUMA RSI Chart

HUMA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HUMA Valuation

Market Cap

299.7M

Price/Earnings (Trailing)

-3.07

Price/Sales (Trailing)

148.67

Price/Free Cashflow

-2.93

HUMA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HUMA Fundamentals

HUMA Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-4.26%

Rev. Growth (Qtr)

6%

HUMA Earnings

Earnings (TTM)

-97.6M

Earnings Growth (Yr)

-145.02%

Earnings Growth (Qtr)

28.97%

HUMA Profitability

Return on Equity

-839.56%

Return on Assets

-88.27%

Free Cashflow Yield

-34.14%

HUMA Investor Care

Shares Dilution (1Y)

43.13%

Diluted EPS (TTM)

-0.61

HUMA Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20262.0M000
20251.7M1.8M1.8M2.0M
20211.5M1.6M1.7M0
2020003.8M1.5M
20190006.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Humacyte, Inc.

HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEhumacyte.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES164

Humacyte, Inc. Frequently Asked Questions

HUMA is the stock ticker symbol of Humacyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 05 2026, market cap of Humacyte, Inc. is 299.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 05 2026, HUMA's PE ratio (Price to Earnings) is -3.07 and Price to Sales (PS) ratio is 148.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HUMA PE ratio will change depending on the future growth rate expectations of investors.